In this study, we identified mutated EGFR amplification as a resistance mechanism in a patient with EGFR T790M‐positive NSCLC who experienced PD on a third‐generation EGFR‐TKI, TAS‐121. This evidence concerns the gene EGFR and non-small cell lung carcinoma.